Multiple biochemical markers in patients with gynecologic malignancies

Donaldson, Elvis S.; Nagell, J.R. van; Pursell, S.; Meeker, William R.; Kashmiri, Rafiah; Devoorde, J. van

doi:10.1002/1097-0142(19800301)45:5<948::aid-cncr2820450519>3.0.co;2-q

Cited by 80 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AFP is a tumour marker which is positive in all cases of endodermal sinus tumour, a germ cell tumour of ovary (Van Nagell et al 1981). Moderate elevation of AFP was found in 43% of advanced epithelial ovarian cancer by Donaldson et al (1980). As in our study, no consistent correlation was found between changes in marker level and the course of the disease (Stanhope et al 1979).…”

Section: Discussioncontrasting

confidence: 68%

Alpha‐fetoprotein in advanced epithelial ovarian cancer

Bose

Mukherjea

1993

BJOG

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 68%

Alpha‐fetoprotein in advanced epithelial ovarian cancer

Bose

Mukherjea

1993

BJOG

View full text Add to dashboard Cite

“…For example, both Evi-l and Epo are expressed in the tubular cells in the kidney (34). In addition, both Evi-J (38) and human chorionic gonadotropin (16) have been found to be expressed in human endometrial carcinomas. We are currently investigating the significance of these findings.…”

Section: T S Ac a A A T A A C A S A C Aa B A T A A C A S A C Aa S A Tmentioning

confidence: 99%

Evi-1, a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein.

et al. 1991

View full text Add to dashboard Cite

Evi-l was originally identified as a common site of viral integation in murine myeloid tumors. Evi-l encodes a 120-kDa polypeptide containing 10 zinc finger motifs located in two domains 380 amino acids apart and an acidic domain located carboxy terminal to the second set of zinc fingers. These features suggest that Evi-l is a site-specific DNA-binding protein involved in the regulation of RNA transcription. We have purified Evi-l protein from E. coli and have employed a gel shift-polymerase chain reaction method using random oligonucleotides to identify a high-affinity binding site for Evi-l. The consensus sequence for this binding site is TGACAAGATAA. Evi-l protein specifically protects this motif from DNase I digestion. By searching the nucleotide sequence data bases, we have found this binding site both in sequences 5' to genes in putative or known regulatory regions and within intron sequences.Many eukaryotic transcriptional regulatory proteins contain one of several DNA-binding motifs, such as a helix-turnhelix or zinc fingers, which confer site-specific, high-affinity binding to transcriptional control sequences in genomic DNA. This binding, under proper conditions, is thought to result in changes in rates of transcriptional initiation by RNA polymerases by mechanisms that are not yet entirely clear (25,37). The first two eukaryotic transcriptional regulatory proteins to be characterized, TFIIIA (17) and Spl (6), were identified by a combination of genetic and biochemical means, by which the binding sites were identified initially as cis-acting regulatory elements. Now that common DNAbinding motifs within proteins have been identified, putative transcriptional factors are often identified on the basis of protein sequence homology.Evi-J was first identified as a common site of ecotropic retrovirus integration in virally induced myeloid tumors of AKXD mice (40). Subsequent cloning and sequencing of the cDNA corresponding to this locus (39) showed that this locus encodes a 120-kDa polypeptide that contains 10 regions with extensive homology to the zinc-binding domains found in several transcriptional regulatory factors and first identified in the Xenopus transcription factor IIIA (36). This amino acid sequence consists of 27 to 30 residues with the consensus sequence (Y/F)XCX2 CX3FX5LX2_3HX34HX5.Current structural models propose that the cysteine and histidine residues chelate a single zinc atom, constraining the intervening amino acids into a looped domain, which is further stabilized by hydrophobic interactions among (Y/F), F, and L (1, 30, 44). DNA binding then occurs between charged amino acids on the exposed face of an alpha helix (which extends from the center of the motif through the histidines) and an estimated 3 to 5 bases along the major groove (1, 7, 21). DNA-binding studies with purified zinc finger regions containing one or several fingers suggest that multiple fingers are necessary to obtain high-affinity, sitespecific DNA binding, perhaps through cooperativity (18,41,44).These sequence compari...

show abstract

“…Although mild or moderate elevations in serum CA125 may be seen with other histological types of ovarian carcinoma, such as endometrioid or clear cell, markedly elevated levels are characteristic of serous carcinoma. Ovarian mucinous neoplasms are less frequently associated with an elevated serum CA125 than non-mucinous tumours5 and levels are typically within the normal range or mildly elevated 6 7. In most ovarian mucinous neoplasms with an elevated serum CA125, it is likely that the CA125 is secreted by reactive mesothelial cells, which are commonly seen in the omentum of patients with ovarian mucinous tumours, rather than by the tumour cells themselves since immunohistochemically the neoplastic cells are usually CA125 negative (W Glenn McCluggage, personal observations).…”

Section: Introductionmentioning

confidence: 99%

Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype

et al. 2010

View full text Add to dashboard Cite

AimsCA19.9 is a monosialoganglioside secreted by mucinous tumours of the gastrointestinal tract, including the pancreas and biliary tree. Limited studies have shown that this tumour marker may also be elevated in primary ovarian mucinous neoplasms, but no study has assessed whether serum CA19.9 levels can be used to predict if a primary ovarian mucinous tumour is benign, borderline or malignant. The aim of this study was to correlate the serum CA19.9 level with the histological features in a large series of primary ovarian mucinous neoplasms.Methods144 cases of primary ovarian mucinous neoplasm (79 benign, 45 borderline and 20 malignant) were identified in which a preoperative serum CA19.9 level had been performed. The association between the serum levels and the histological subtype and a variety of other parameters was investigated. In a subset of cases, immunohistochemical staining for CA19.9 was performed on tumour blocks.ResultsSerum CA19.9 levels were elevated in 27%, 38% and 40% of mucinous cystadenomas, borderline mucinous tumours and mucinous carcinomas, respectively. Markedly elevated levels of serum CA19.9 were observed in each group, with the highest serum CA19.9 measurements being noted in borderline mucinous tumours. There was no relationship between the serum CA19.9 level and whether the tumours were benign, borderline or malignant (Kruskal–Wallis test p value=0.32). A weak but statistically significant correlation was found between tumour maximum dimension and CA19.9 level (Spearman's rank correlation coefficient=0.17, p=0.04). In those cases in which CA19.9 immunohistochemistry was performed, all tumours showed positive staining for CA19.9, with 60% of these cases being associated with an elevated serum CA19.9 level.ConclusionPreoperative CA19.9 levels cannot be used to predict whether a suspected ovarian mucinous tumour is benign, borderline or malignant. Markedly elevated serum levels (>1000 U/ml) may be found in benign mucinous neoplasms as well as in borderline and malignant tumours.

show abstract

Multiple biochemical markers in patients with gynecologic malignancies

Cited by 80 publications

References 26 publications

Alpha‐fetoprotein in advanced epithelial ovarian cancer

Alpha‐fetoprotein in advanced epithelial ovarian cancer

Evi-1, a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein.

Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype

Contact Info

Product

Resources

About